Abstract
Objective To observe the regulation of platelet membrane glycoprotein CD61,CD62P in septic inflammation. Methods Make the model of sepsis by cecal ligation and puncture(CLP). Sixty male BALB/c mice were randomly divided into 4 groups(negative control,sham operation,CLP,CLP+ Tirofiban). The platelet counts, expressions of CD61 and CD62P in peripheral platelets, levels of tumor necrosis factor-α(TNF-α) and interleukin(IL)-6 in serum were measured at 24 h after operation. Results Compared with those of negative control group[(289.7±45.9)×106/L], sham operation group[(267.7 ±25.4)×106/L]and CLP+ Tirofiban group[(217.0±29.7)×106/L], the platelet count was lower in mice with CLP[(167.0±31.4)×106/L, P< 0.01]. The expressions of CD61[(91.22±2.96)%], CD62P[(7.87±2.90)%], TNF-α[(723.51±96.65) ng/L] and IL-6[(757.35±131.48) ng/L] in mice with CLP increased significantly(P< 0.01). However, the expressions of CD61[(67.50± 8.67)%], CD62P[(3.53±0.78)%], TNF-α[(426.38±16.69) ng/L]and IL-6[(482.32±56.73) ng/L]in mice with CLP+ Tirofiban were all lower than that of CLP group(P< 0.01).There is positive correlation between the expression of platelet membrane glycoprotein and the expression of inflammatory factors in mice with CLP. Conclusion Platelet activation is closely related to the inflammatory response of sepsis. Down-regulation of platelet membrane glycoprotein can significantly attenuate the septic inflammation. Key words: Sepsis; Platelet membrane glycoprotein; CD61; CD62; Inflammatory reaction
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.